Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-1: DTG + 3TC vs DTG + TDF/FTC in HIV-1 Naive Adults
NCT02831673Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Jul 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of dolutegravir, lamivudine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Started Jul 2016; status: completed.
02
Drugs
dolutegravirlamivudine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02831673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02831673.